Thyroid Stimulating Hormone Receptor (TSHR) Intron 1 Variants Are Major Risk Factors for Graves' Disease in Three European Caucasian Cohorts

• Rafał Płoski ,

  Contributed equally to this work with: Rafał Płoski, Oliver J. Brand

  Affiliations Department of Medical Genetics, Medical University of Warsaw, Warsaw, Poland, Department of Forensic Medicine, Medical University of Warsaw, Warsaw, Poland

  ⨯
• Oliver J. Brand ,

  Contributed equally to this work with: Rafał Płoski, Oliver J. Brand

  * E-mail: oliver.brand@ocdem.ox.ac.uk

  Affiliations Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, United Kingdom, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom

  ⨯
• Beata Jurecka-Lubieniecka,

  Affiliation Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

  ⨯
• Maria Franaszczyk,

  Affiliation Department of Medical Genetics, Medical University of Warsaw, Warsaw, Poland

  ⨯
• Dorota Kula,

  Affiliation Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

  ⨯
• Paweł Krajewski,

  Affiliation Department of Forensic Medicine, Medical University of Warsaw, Warsaw, Poland

  ⨯
• Muhammad A. Karamat,

  Affiliation Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, United Kingdom

  ⨯
• Matthew J. Simmonds,

  Affiliations Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, United Kingdom, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom

  ⨯
• Jayne A. Franklyn,

  Affiliation Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, United Kingdom

  ⨯
• Stephen C. L. Gough,

  Affiliation Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom

  ⨯
• Barbara Jarząb,

  Affiliation Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

  ⨯
• Tomasz Bednarczuk

  Affiliation Department of Endocrinology, Medical University of Warsaw, Warsaw, Poland

  ⨯